Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

Clinical trial NCT06606730 · RECRUITING

Trial details

NCT number: NCT06606730
Sponsor: UNICANCER
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancers Triple Negative Breast Cancer (TNBC)

Start date: 2025-07-23
Primary completion: 2033-01-01
Enrollment: 2454

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.